ArticleApplied biochemistry and biotechnology2026
Identification of Diosmetin, Arbutin, and Phenyl Glucoside as Novel Inhibitors from Origanum majorana Targeting Human Cyclooxygenase-2 Enzyme: Insight from Virtual Screening, MD Simulation and Density Functional Theory.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is a key factor in developing many diseases due to its complex pathogenesis. While Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) targeting Cyclooxygenase-2 (COX-2) demonstrate therapeutic efficacy, their clinical utility is limited by significant adverse effects, including myocardial infarction, gastrointestinal disturbances, and abdominal discomfort. Notably, Origanum majorana has demonstrated anti-inflammatory properties, but its bioactive constituents targeting (COX-2) remain unexplored. In this study, we employed a structure-based pharmacophore model using the crystal structure of Human Cyclooxygenase-2 (COX-2; PDB ID: 5F1A) to virtually screen 283 phytochemicals from O. majorana. Molecular docking and interaction analyses revealed three promising compounds (Diosmetin, Arbutin, and Phenyl glucoside) as potential (COX-2) inhibitors, exhibiting strong binding affinities. Pharmacokinetic profiling, encompassing absorption, distribution, metabolism, excretion, and toxicity (ADMET) assessment, as well as drug-likeness evaluation, revealed favorable properties for these compounds. To evaluate their binding stability, (100 ns) molecular dynamics (MD) simulations were performed, analyzing root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), hydrogen bonds, solvent-accessible surface area (SASA), and principal component analysis (PCA). Binding free energies calculated via molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) demonstrated superior affinity for Diosmetin (–37.21 kcal/mol), Arbutin (–23.16 kcal/mol), and Phenyl glucoside (–20.23 kcal/mol) compared to the reference ligand (–16.8 kcal/mol). Additionally, density functional theory (DFT) calculations assessed electronic properties, including HOMO-LUMO energy gaps, global reactivity descriptors, and molecular electrostatic potential, further supporting their potential as (COX-2) inhibitors. Our integrated computational approach identifies these phytochemicals as promising (COX-2) inhibitors, warranting further experimental validation through in vitro and in vivo studies to assess their potential as natural anti-inflammatory therapeutics.
Indexed as
Identifiers
41557214What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.